Mpci.Ca
MPCI.CA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of prescription medications and related healthcare products.
Business. MPCI.CA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of prescription medications and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MPCI.CA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of prescription medications and related healthcare products.
MPCI.CA maintains a strong liquidity position, with a current ratio of 2.15 and a significant cash and equivalents balance of $678.6 million. The company's price-to-book ratio of 2.76 and price-to-tangible-book ratio of 2.76 suggest that the market values the company's equity at a premium relative to its book value. The low debt-to-equity ratio of 0.13 indicates a conservative capital structure with minimal leverage.
In terms of profitability, MPCI.CA reports a return on equity (ROE) of 65.58% and a return on assets (ROA) of 33.85%, both of which are well above the typical thresholds for the pharmaceutical industry. The company's net income of $505.28 million and operating income of $529.35 million reflect strong operational performance. These metrics suggest that MPCI.CA is effectively utilizing its equity and asset base to generate returns.
MPCI.CA's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly if demand for its products fluctuates in its primary market.
The company's growth trajectory is supported by a strong free cash flow of $474.72 million and a positive operating cash flow of $86.89 million. While specific revenue growth projections for the current and next fiscal years are not provided, the company's robust cash flow generation and low capital expenditure of $21.23 million suggest a focus on maintaining operational efficiency rather than aggressive expansion.
MPCI.CA's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and substantial cash reserves further support its strong liquidity position. There is no evidence of dilution potential in the basic shares outstanding, as the diluted shares are equal to the basic shares.
Recent filings and transcripts do not indicate any significant events that would impact the company's financial performance or strategic direction. The absence of notable events suggests a stable operating environment for MPCI.CA.
- MPCI.CA has a strong liquidity position with a current ratio of 2.15 and significant cash reserves.
- The company's ROE of 65.58% and ROA of 33.85% indicate high profitability and efficient use of assets.
- MPCI.CA's revenue is concentrated in a single segment, which may increase its exposure to market fluctuations.
- The company's low debt-to-equity ratio and strong free cash flow suggest a conservative and financially stable capital structure.
- No immediate liquidity or dilution risks are identified, and the company's financial performance appears stable.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- MPCI.CA Market data — financials · 2026-05-28